tbuckley/cabot-search huggingface dataset:
Clinical applications of vancomycin and norvancomycin in hospitalized neurosurgical patients
Authors: Hua Ouyang, Fan Yang
Journal: BMJ (2014)

The medical records of 108 inpatients treated with vancomycin and norvancomycinin were collected and analyzed retrospectively. And 78.7% of all cases were used for therapy and 21.3% for prevention. The pathologic examination submission rate was 88.9% (n=96). The drug utilization index (DUI) of norvancomycin was 0.95 and vancomycin 0.92. The proportion of combination use was 86.1% and a maximum of 3 antibiotics were used. There were 6.5% cases of doubtful adverse drug reaction.The inpatient uses of vancomycin and norvancomycin are basically rational. Indications should be mastered strictly. Empirical and prophylactic uses should be minimized to prevent and delay drug resistance strain from spreading and prolong effectiveness. Necessary therapeutic drug monitoring is required.


Key words: 
Vancomycin; Norvancomycin; Rational drug use
Application of needle video-assisted thoracoscopy in diagnosis and treatment for solitary pulmonary nodule
Authors: Xin-yi Wu
Journal: BMJ (2010)

Lung wedge resections under needle video-assisted thoracoscopy were performed in 45 casesof SPIN. Those in whom lung cancer was confirmed received pneumonectomy subsequently. Needle video-assisted thoracoscopic surgery was performed successfully in all patients. Pathological examination showedbenign tumors in 22 cases and malignant lesions in 23 cases. For malignant cases radical resection of lunglobe was performed with assisted small auxiliary incision. The operation time was 25 - 180 min; the meanblood lose was less than 200 ml; the length of hospital stay was 3 - 20 d. There were no serious post-operational complications and fatal cases. Needle video-assisted thoracoscopic surgery is of value in diagnosisand treatment of solitary pulmonary nodule with satisfactory therapeutic effects.

Key words: 
Coin lesion, pulmonary;  Thoracoscopes
再论社区卫生服务的基本概念
Authors: 吴春容
Journal: BMJ (2004)

从1996年12月召开的全国卫生工作大会及1997年1月15日颁发的 明确提出要改革城市卫生服务体系,积极发展社区卫生服务,逐步形成功能合理、方便群众的卫生服务网络,至今已有6个多年头,我国的社区卫生服务从无到有,从试点阶段到全面实施阶段,已经积累了许多宝贵的经验,取得了可喜的成绩。
Colorectal lipoma: clinical analysis of 9 cases
Authors: Yixun Zhang, Bo Jiang, Haiyi Liu, Wenqi Bai, Wenyuan Wang
Journal: BMJ (2017)

Nine cases of colorectal lipoma who were admitted from January 2005 to December 2016 were reported. The pathological diagnosis was confirmed after surgery, and all 9 cases were cured and discharged. All patients were followed up and were alive by January 2017.


Key words: 
Colorectal neoplasms; Lipoma; Pathological conditions, signs and symptoms
广泛性焦虑障碍的认知行为治疗
Authors: 沈亮亮, 江孙芳, 劳力敏, 祝墡珠
Journal: BMJ (2012)

广泛性焦虑障碍(GAD)是慢性精神疾病,核心症状是慢性病理性担忧,常导致患者心理社会功能的严重下降及卫生资源的过度利用.认知行为疗法(CBT)被广泛认为是治疗该病的有效心理学疗法.本文重点介绍CBT在GAD中运用的内容和方法,以及在GAD治疗中的效果及相关影响因素。
Combating Discrimination in Medical Education
Authors: Quentin R. Youmans
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Analysis of the expression of matrix metalloproteinase and tissue inhibitor of metalloproteinase in gestational trophoblastic diseases
Authors: 戴淑真, 王灵芝, 李玉军
Journal: BMJ (2007)

目的 探讨基质金属蛋白酶(MMP)及其抑制物(TIMP)在妊娠滋养细胞疾病中的表达水平与其侵袭程度的关系.方法 采用免疫组织化学PV-6000法测定49例葡萄胎(其中8例发生恶变,为葡萄胎恶变组;另外41例为葡萄胎未恶变组)、6例侵蚀性葡萄胎(侵蚀性葡萄胎组)、2例绒毛膜癌(绒毛膜癌组)和18例正常早孕绒毛组织(正常绒毛组)的MMP-7、MMP-9、TIMP-1、TIMP-2的表达及分布情况.结果 MMP-7、MMP-9、TIMP-2、MMP-9/TIMP-1值在绒毛膜癌、侵蚀性葡萄胎及葡萄胎恶变组中的表达分别高于正常绒毛和葡萄胎未恶变组(F=10.950,7.760,7.304,3.442;P均＜0.05);MMP-7、MMP-9、TIMP-1、TIMP-2表达在正常绒毛和葡萄胎未恶变组之间差异均无统计学意义.结论 MMP和TIMP表达水平的高低与妊娠滋养细胞疾病的侵袭程度有关。
Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.
Authors: Aida Bujosa Rodríguez, Consolacion Molto, Thomas J Hwang, Kerstin Noëlle Vokinger, Jose Carlos Tapia, Ignasi J. Gich Saladich, Arnoud J. Templeton, Agusti Barnadas, Eitan Amir, Ariadna Tibau
Journal: Journal of Clinical Oncology (2020)

7052 Background: Initial drug approval is often based on surrogate endpoints. Definitive outcomes like Overall Survival (OS) or Quality of life (QoL) may not be available. Here, we evaluate changes in the magnitude of clinical benefit using the American Society of Clinical Oncology Value Framework (ASCO-VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) comparing the time of approval to the most recent available data for cancer drugs approved by the US Food and Drug Administration (FDA) between 2006 and 2015. Methods: We examined data on trials supporting FDA accelerated (AA) and regular (RA) cancer drug approvals between January 2006 and December 2015. We performed a systematic search of Pubmed and ClinicalTrials.gov to identify updated OS and/or QoL data, with follow up through April 2019. For AA drugs we analysed initial and confirmatory trials as follow-up. ASCO-VF and ESMO-MCBS grades were applied for trials at approval and after marketing. We explored variables associated with improved clinical benefit scores using multivariable logistic regression. Results: We identified 102 trials supporting the approval of 59 drugs for 96 solid tumour indications. Of these indications, 22 (23%) were granted AA and 21 (95%) were converted to RA. At time of approval, 38% of trials showed improved OS and 17% improved QoL. Substantial clinical benefit was observed in 26% of initial approval trials using ESMO-MCSB and in 34% using ASCO-VF. After a median post-marketing period of 3.3 years, updated results changed substantial clinical benefit in 20 trials with ESMO-MCBS (19 upgrades, 1 downgrade) and in 23 trials using ASCO-VF (19 upgrades, 4 downgrades). For 25% of trials no updated information was found. In the palliative setting, multivariable analysis showed association between improved ASCO-VF scores and initial approvals based on single-arm trials (OR 9.21, 95%CI 1.36-62.29, P=0.023), drugs with companion diagnostics (OR 4.95, 95%CI 1.01-24.22, P=0.049) and second or later lines (OR 7.80, 95%CI 1.35-45.02, P=0.022) while for ESMO-MCBS, drugs with companion diagnostics (OR 6.86, 95%CI 1.82-25.86, P=0.004) and immunotherapy drugs (OR 6.42, 95%CI 1.27-32.59, P=0.025) were associated with greater clinical benefit. Conclusions: Drugs with companion diagnostic tests, immunotherapy as well as approved based on single-arm trials were associated with increased clinical benefit after marketing approval. For a quarter of trials there were no updated data in the post-marketing period.
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
Authors: Matthew P. Goetz, Erika Paige Hamilton, Mario Campone, Sara A. Hurvitz, Javier Cortes, Stephen R. D. Johnston, Guy Heinrich Maria Jerusalem, Hillary Graham, Hong Wang, Lacey Litchfield, Valerie Malyvanh Jansen, Miguel Martin
Journal: Journal of Clinical Oncology (2020)

3519 Background: An understanding of the mechanisms of acquired resistance to CDK4 &amp; 6 inhibitors, either alone or with endocrine therapy (ET), is an unmet need. Abemaciclib is a CDK4 &amp; 6 inhibitor approved for treatment of HR+, HER2- advanced breast cancer (ABC). Here we evaluated acquired genomic alterations detected in circulating tumor DNA (ctDNA) from patients (pts) treated with abemaciclib + nonsteroidal aromatase inhibitor (AI) or placebo + AI in MONARCH 3 or abemaciclib monotherapy in nextMONARCH 1. Methods: MONARCH 3 randomized postmenopausal women with HR+, HER2- ABC with no prior systemic therapy in the advanced setting to abemaciclib (150 mg Q12H) or placebo + AI. nextMONARCH 1 randomized women with HR+, HER2- metastatic breast cancer who had progressed on or after prior ET and CT to abemaciclib (150 mg Q12H) + tamoxifen, abemaciclib (150 mg Q12H), or abemaciclib (200 mg Q12H) + loperamide. Plasma from pts in the abemaciclib or placebo + AI arms (MONARCH 3) or abemaciclib monotherapy arms (nextMONARCH 1) was analyzed by the Guardant360 assay to identify potential tumor-related genomic alterations including point mutations, indels, amplifications, and fusions acquired at EOT in comparison with baseline. Results: For MONARCH 3, commonly acquired alterations at EOT included ESR1 (17%), TP53 (10%), EGFR (8%), FGFR1 (7%), and PDGFRA (7%) in the abemaciclib + AI arm, and ESR1 (31%), TP53 (10%), and BRCA1 (7%) in the placebo + AI arm. Acquired alterations more frequent for abemaciclib + AI pts included RB1 (6%), MYC (5%), and AR (5%), compared to 0% in the placebo + AI arm (p = 0.008 RB1; p = 0.015 MYC or AR). In contrast, acquired ESR1 alterations were less frequent with abemaciclib + AI vs placebo + AI (17% vs 31%, p = 0.038). In nextMONARCH 1, the most commonly acquired alterations with abemaciclib monotherapy were in TP53 (10%), EGFR (9%), RB1 (9%), MYC (9%), and MET (8%). In addition, acquired alterations in ESR1 (6%) and AR (3%) were also found. PIK3CA alterations were not frequently acquired (abemaciclib + AI 1%, placebo + AI 6%, abemaciclib monotherapy 5%). Conclusions: Acquired genomic alterations potentially associated with emerging mechanisms of resistance to abemaciclib alone or in combination with AI may include RB1, MYC, or AR alterations, while the acquisition of ESR1 alterations was less common in pts treated with abemaciclib + AI compared to placebo + AI. These findings are hypothesis-generating and provide insight into mechanisms of resistance to abemaciclib vs ET. Clinical trial information: NCT02246621, NCT02747004 .
股前外侧肌瓣桥式游离移植修复小腿软组织缺损
Authors: 张功林, 陈克明, 张军华, 王世勇
Journal: BMJ (2011)

小腿高能量损伤常导致胫前软组织缺损伴骨与肌腱外露,难以用常规局部带蒂皮瓣转移修复时,需行吻合血管的组织移植修复[1-2].但如肢体损伤较重,伴有主要血管损伤或缺损,局部无可供吻合的血管,采用健肢血管行桥式交叉吻合技术治疗可取得满意效果[3-4]。
Extracorporeal shock wave therapy for treatment of heel pain
Authors: Baolin Li, Qingbo Kong, Wei Zhao, Lixue Ma
Journal: BMJ (2015)

To explore the therapeutic efficacy of extracorporeal shock wave (ESW) for persistent heel pain. A total of 98 patients of persistent heel pain were randomly divided into ESW treatment and control groups (n=49 each). Treatment group had ESW while control group received infrared physical therapy. And their visual analogue scale (VAS) scores were assessed. After one course of treatment, VAS heel pain and function scores were (39.6±6.2) and (25.1±4.6) in ESW group versus (32.3±6.5) and (17.4±7.2) in control group. And before treatment, (16.5±4.6) and (14.4±8.6), (16.1±4.7) and (14.6±8.4) respectively. Heel pain significantly decreased with functional improvement (all P<0.05). After one course, the effective rate was 65% (32/49) in treatment group. And the improvement rate of 31% (15/49) was better than control group [27% (13/49) and 63% (31/49)] (all P<0.05). ESW treatment of persistent heel pain was more efficacious than physical therapy and it could be applied clinically.


Key words: 
Shock waves; Heel spur
Abstract 12637: Temporal Changes in Resting Heart Rate in Young Adults, Long-term Cardiac Structure and Function, and Incident Heart Failure and Cardiovascular Disease in Middle Age
Authors: Chike C Nwabuo, Duke Appiah, Henrique T Moreira, Henrique D Vasconcellos, Queen N Aghaji, Bharath Ambale Venkatesh, Jamal S Rana, Norrina B Allen, Donald M Lloyd-Jones, Pamela Schreiner, Samuel Gidding, Joao A Lima
Journal: Circulation (2019)

Background: The prognostic significance of temporal changes in resting heart rate (RHR) in young adults for premature heart failure (HF) and cardiovascular disease (CVD) is not well-studied. Method...
Clinical analysis of Takayasu's arteritis with cardiomyopathy
Authors: Hua Zhong, Weiguo Zhu, Xue Lin, Yunyun Fei, Wei Zhang, Xiaowei Yan
Journal: BMJ (2014)

The clinical data of 13 patients diagnosed as Takayasu's arteritis with cardiomyopathy in Peking Union Hospital were reviewed. Echocardiography showed cardiomegaly (left chambers mainly), diffuse weakened myocardial wall movement and reduced left ventricular ejection fraction. Dilated cardiomyopathy was diagnosed in two patients. Glucocorticoid and cyclophosphamide were the essential medication for treatment. One patient died, 1 patient was aggravated and the disease condition in remaining 11 patients was stable or improved. Takayasu's arteritis with cardiomyopathy is a rare disease and it attacks younger people. It is difficult to identify at onset, and the disease deteriorates rapidly. Echocardiography should be performed earlier to evaluate the heart function for early diagnosis and treatment. Administration of large dose of glucocorticoid and cyclophosphamide at early stage may improve the prognosis.


Key words: 
Takayasu's arteritis; Cardiomyopathies
A patient with diabetic nephropathy treated with glucagon like peptide-1 receptor agonist
Authors: Yao Xu, Jiaqi Yao, Xiujing Wang
Journal: BMJ (2017)

1例于2002年诊断为2型糖尿病并糖尿病肾病(DN)患者，行口服降糖治疗；2008年患高血压，糖化血红蛋白(HbA1c) 6.1%，自行监测血压，血压降至130/80 mmHg(1 mmHg＝0.133 kPa)，随访至2014年12月蛋白尿始终无改善，始予胰高血糖素样肽-1受体激动剂(第1个月5 U/d、第2个月始10 U/d)治疗。治疗9个月后，患者体质量下降4.3%，BMI下降4.5%，腰围减少4.5%，腹腔内脏脂肪面积减少9.0%，24 h尿白蛋白下降了88.3%(818.0降至95.8 mg)。提示胰高血糖素样肽-1受体激动剂对DN具有治疗作用，且可能不依赖于其降糖、降压及减重的作用。
A survey on depression status in elderly patients from one community health service center in Shanghai
Authors: Juan Shou, Shanzhu Zhu, Chunhui Liu, Yao Liu, Shen Liu, Wentao Zheng, Jian Gong
Journal: BMJ (2014)

Objective
To survey the prevalence of depressive symptoms and related risk factors among elderly patients in primary care settings in Shanghai.


Methods
Total 1 332 patients aged 60 or above, who were visited Shanghai Shimen Erlu Community Health Service center from April to June of 2011, were included in the survey, including 554 males and 778 females with an average age of 72±11.A screening questionnaire based on the patient health questionnaire-9(PHQ-9)was applied in the survey, the sociodemographic and health-related variables were analyzed, and social support scale was evaluated.


Results
Total 258 (19.6%) patients had depressive symptoms in this study and 13.4%(176/1 318) of them had minor depression.The average social support score was (33.2±8.9)．There were significant differences in subjective support, objective support and usage of support between the depressive and non-depressive patients (t＝6.37, 3.83, 2.72 respectively，P<0.01)．There were 5 variables into logistic regression equation including relationship with spouses, life satisfaction, percentage of medical costs over total household expenses, outdoor exercise and objective social support.


Conclusions
Marital disharmony, poor life satisfaction, the burden of medical costs, less exercises and less objective support are the main risk factors associated with depression status of elderly patients in the community.


Key words: 
Community health services; Aged; Depression
MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.
Authors: Patrick Neven, Stephen R. D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Nikolaevna Burdaeva, Meena Okera, Norikazu Masuda, Han A. Koh, Eva-Maria Grischke, Pier Franco Conte, Yi Lu, Nadine Haddad, Karla Hurt, Peter A. Kaufman, Antonio Llombart-Cussac, George W. Sledge
Journal: Journal of Clinical Oncology (2020)

1061 Background: In MONARCH 2 (M2), abemaciclib (A), an oral selective cyclin dependent kinase 4 &amp; 6 inhibitor, + fulvestrant (F) demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to placebo (P) + F in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). Numerically more pronounced PFS &amp; OS improvement was noted in subgroups (Sub) with visceral (V) disease and primary endocrine resistance. Here we report efficacy data for M2 with respect to 1L and 2L Sub (last line of endocrine therapy [ET] in (neo)adjuvant and metastatic setting, respectively). Methods: M2 (NCT02107703) was a global, randomized, double-blind Phase 3 trial of A+ F (N = 446) or P + F (N = 223) in women with ET resistant (ETR) HR+, HER2- ABC regardless of menopausal status. Patients (pts) were stratified by site of metastasis (V, bone-only, or other) and resistance to prior ET (primary vs secondary). Exploratory Sub analyses of PFS and OS were conducted among pts in the ITT population with 1L vs 2L. Hazard ratios (HR) were estimated using Cox models with a test of interactions of Sub with treatment performed. Results: At data cut-off (June 20 th , 2019), the effect of A + F vs P + F was consistent across 1L (N = 265/133) and 2L (N = 170/86) Sub, with no statistically significant interaction for PFS (p = 0.341) or OS (p = 0.265). For 1L pts, improvements in PFS (HR: 0.57; 95% CI:0.45, 0.73) and OS (HR: 0.85; 95% CI:0.64, 1.14) were observed. Similar efficacy results were observed for 2L pts (PFS: HR: 0.48; [95% CI: 0.36, 0.64]; OS HR: 0.66 [95% CI: 0.46, 0.94]). The numerically largest effects in the 1L population were noted in pts with less favorable prognostic factors such as primary ETR (PFS: HR 0.40 [95% CI: 0.26, 0.63]; OS: HR 0.58 [95% CI:0.35, 0.97]) and V disease (PFS: HR 0.54 [95% CI: 0.39, 0.73]; OS: HR 0.82 [95% CI: 0.57, 1.17]). Conclusions: The statistically significant benefit observed in the M2 study was observed across 1L and 2L patients. In 1L patients (A+F Arm), improvements were observed for PFS and OS with the most pronounced effects noted in patients with less favorable prognostic factors. Clinical trial information: NCT02107703 .
Novel association of pre-chemotherapy immune cell profiles with functional decline and resilience in women with breast cancer receiving chemotherapy.
Authors: Nikesha Gilmore, Supriya Gupta Mohile, Huiwen Xu, Kah Poh Loh, Amber Kleckner, Elizabeth Belcher, Lianlian Lei, Po-Ju Lin, Lora Rose Weiselberg, Jerry W. Mitchell, Mary Ontko, Michelle Christine Janelsins
Journal: Journal of Clinical Oncology (2020)

549 Background: Chemotherapy adversely affects physical function. While many patients recover after treatment (i.e. are resilient), some are unable to return to their pre-treatment function (i.e. are non-resilient). Since immune dysfunction may play a role in functional decline, we assessed the relationship of pre-chemotherapy immune cell profiles with functional decline and resilience in women with breast cancer receiving chemotherapy. Methods: This study was based on a large nationwide cohort study in women with stage I-III breast cancer. Physical function was measured by the Functional Assessment of Cancer Therapy: General – Physical subscale (FACT-PWB) ≤7 days before chemotherapy (T1), ≤1 month after chemotherapy (T2), and 6 months after T2 (T3). Functional decline at T2 and T3 was defined as &gt; 1 point decrease (clinically meaningful difference) in FACT-PWD score from T1. Patients were considered non-resilient if they had T2 functional decline and did not return to within 1 point of their baseline FACT-PWB score by T3. Immune cell counts, neutrophil:lymphocyte ratio (NLR), and lymphocyte:monocyte ratio (LMR) were obtained at T1. Multivariate logistic regressions were used to determine whether immune cell counts and ratios were associated with functional decline and being non-resilient controlling for baseline FACT-PWD, age, race, education, and marital status. Results: One-third of patients (178/529; mean age 53, range 22-81) had functional decline from T1-T3. Of the 59% (n = 310) of patients with functional decline at T2, 50% (n = 147) did not recover by T3 (i.e. were non-resilient). Patients with a low ( &lt; median) NLR at T1 were twice as likely to have functional decline by T3 than those with a high (≥ median) NLR [Adjusted Odds Ratio (AOR) 1.8, 95% CI: 1.2-2.8, p &lt; 0.01]. Similarly, in patients with functional decline at T2, those with a low NLR at T1 were twice as likely to be non-resilient than those with high NLR (AOR: 1.9, 95% CI: 1.1-3.2, p = 0.01). Conversely, patients with high T1 lymphocytes were twice as likely to be non-resilient than those with low lymphocytes (AOR: 1.8, 95% CI: 1.1-3.1, p = 0.02). Conclusions: One-third of women with breast cancer have clinically meaningful, persistent functional decline six months after completing chemotherapy. Higher pre-chemotherapy lymphocytes and lower NLR may be useful to identify which women are at increased risk of functional decline and reduced ability to regain baseline physical function. These findings can inform interventions to ameliorate this decline.
Single cell dissociation from mouse tumor samples and analysis on BD FACSLyric Flow Cytometer.
Authors: Wei Huang, Nate Pereira, Patrick Thomas Neuhoefer, Aaron Middlebrook, Smita Ghanekar
Journal: Journal of Clinical Oncology (2020)

e15245 Background: Single cell multiomics analysis of tumor cells and tumor infiltrating immune cells using high parameter flow cytometry and single cell genomics technologies is a powerful approach in the investigation of tumor biology and in the discovery of new drug targets and biomarkers. The preparation of single cells from solid tumor samples often involves a physical dissociation step in combination with an enzymatic digestion step. Methods: The effect of the tumor cell dissociation process on the phenotypic properties of single cells isolated from solid tumor samples were analyzed using a 12-color reagent panel on the BD FACSLyric flow cytometer. Specifically, spontaneous pancreatic tumor samples from genetically modified mice were processed using a manual dissociation process with a scalpel blade as well as an integrated tumor sample dissociation process with the prototype Singulator instrument with various protocol settings. The BD Horizon Dri Tumor &amp; Tissue Dissociation Reagent (TTDR) reagent was used for the enzymatic step in all sample preparations. The yield, viability, and frequency of tumor cells and different subsets of leukocytes were measured for each tumor-derived single cell sample preparation. On the Singulator system, cell yield reached a plateau with highest viability at the 30-min process time and a higher percentage of tumor cells was obtained compared to the manual sample processing method. Results: The relative frequencies of T cells, B cells, myeloid cells and macrophages also changed in different sample preparation methods. However, the spatial heterogeneity in the tumor section and cell composition may contribute to these differences and would require more in-depth analysis. In summary, these results suggest that there are many variables in the tumor sample single cell dissociation process that could impact the downstream study results, particularly for multiomics studies. Conclusions: This study highlights the need for optimization and standardization of the sample processing methodologies for downstream analysis. Disclaimers: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Class 1 Laser Product. BD, the BD Logo, FACSLyric, and Horizon are trademarks of Becton, Dickinson and Company. © 2020 BD and its subsidiaries. All rights reserved.